News for 'POSC' - (Positron Showcased at NASDAQ Marketsite)
INDIANAPOLIS, May 06, 2010 (BUSINESS WIRE) -- Positron Corporation (OTCBB:POSC)
(the "Company") a molecular imaging solutions company focused on Nuclear
Cardiology, announced the highlights from the Company's presentation before
NASDAQ on May 5, 2010.
The Management of Positron Corporation introduced the Company at the NASDAQ
Marketsite. This forum is of great value to Positron since it provides broad
exposure and access to a far reaching investment community.
The Company set out to explain the foundation of its business, the confirmation
of a strategic partnership and potential revenue. Management discussed most all
aspects of the Company's plans which it was at liberty to disclose. A transcript
of the presentation will be filed with the Securities and Exchange Commission on
a Form 8-K immediately when it becomes available in coming days.
Positron representatives did confirm an agreement with an industry leading
strategic partner that will give the Company the ability to greatly expand the
Company's revenue stream and our position in the molecular imaging market by
offering imaging systems and radiopharmaceutical distribution. Patrick Rooney,
Positron Corporation's CEO states, "We would have liked to introduce a certain
synergistic business partner as was stated in the press; however it was the
recommendation of both companies to not disclose further details due to a
potential expansion relationship and certain strategic competitive advantages.
We anticipate additional information will be disclosed in the near future."
Positron also gave guidance as to its target revenue. Based on the Company's
research and unique positioning in the marketplace, Positron projects
significant sales growth quarter over quarter, year over year. Positron projects
that in the next 5 years the nuclear cardiology market will approach $1.5
Billion in revenue annually. The projections reflected sales from Positron's PET
device and radiopharmaceutical devices and services. Positron may potentially
achieve greater revenue as it expands into new markets with broader indications
that we expect will be fully supported by Medicare and private payers.
About Positron: Positron founded in 1983, is a molecular imaging company focused
on Nuclear Cardiology. Positron utilizes its proprietary product line to provide
unique solutions to the Nuclear Medicine community ranging from imaging systems
to radiopharmaceutical distribution. Positron products include: the Attrius(TM),
a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear
Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the
Tech-Assist(TM), a radiopharmaceutical injection shield. Positron is
headquartered in Indianapolis, Indiana. More information about Positron is
available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and estimates and are not guarantees of
future performance and may involve known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or achievements of
Positron Corporation to be materially different from future results, performance
or achievements expressed or implied by such forward-looking statements. Our
actual results may differ materially from the results anticipated in these
forward-looking statements due to a variety of factors, including, without
limitation those set forth as "Risk Factors" in our filings with the Securities
and Exchange Commission.
For further information please contact Positron Corporation at (317) 576-0183.
SOURCE: Positron Corporation
CONTACT:
Positron Corporation
Patrick Rooney
(317) 576-0183
